Leading Justice is a full-service marketing company working with law firms on a cash buy basis to sign up fully-qualified, fraud-free Pradaxa cases. Here at Leading Justice, we can fulfill your firm’s Pradaxa advertising needs and help you sign up cases via internal cash buys. Our clients simply pay an agency fee to cover the cost of Pradaxa advertising, plus a fee for each case we sign, and any data we generate for your firm belongs to you. We also cross-qualify all of our contacts, which means any data we generate that isn’t eligible for the target campaign is reviewed to determine whether it qualifies for another type of claim. By using advanced approaches to target contacts specifically related to Pradaxa and side effects like internal bleeding, Leading Justice will increase your firm’s Pradaxa case load. If you are interested in helping victims of alleged Pradaxa side effects, our extensive consumer reach and direct advertising strategies at Leading Justice give you the competitive edge and confidence to allocate your full budget, with the knowledge that your money is being used in the best way possible.
Each law firm we work with at Leading Justice plays an important role in how we categorize claims as qualified or not. With our experience working alongside plaintiff law firms, we are able to recognize a great case when we see one, but we will also customize our Pradaxa case intake specifications to the exact criteria you are seeking. So, if your firm has specific qualifying case criteria you would like us to use, we will train our intake specialists to apply your criteria to each phone call and email they receive. By getting rid of the middle man, Leading Justice offers clients an opportunity for internal cash buys of Pradaxa data with no chance of fraud.
Our Take on Pradaxa Internal Bleeding
Pradaxa is the brand name of a popular blood thinner manufactured by Boehringer Ingelheim and introduced in the United States in 2010. Despite claims by the drug company that Pradaxa was a superior alternative to the already established anticoagulant warfarin, serious concerns about potential Pradaxa side effects began to surface before the medication was even on the market for a year. In September 2011, a Pradaxa investigation was launched in New Zealand after the sudden deaths of five elderly patients taking the blood thinner, all of which were connected to internal bleeding and hemorrhaging complications. According to a letter sent to Boehringer Ingelheim by Japanese regulators prior to this investigation, during the course of five months, a whopping 81 elderly patients suffered heavy bleeding side effects associated with Pradaxa, and five died.
In addition to internal bleeding, research shows that Pradaxa may increase a patient’s risk of other serious medical events as well, including heart disease, heart attack and stroke – the very condition that the blood thinner was designed to prevent. According to a recent report, more than 1,500 Pradaxa claims have already been brought against Boehringer Ingelheim, and as more and more Pradaxa patients become aware of the risks associated with the anticoagulant, additional product liability lawsuits are expected in the future.